Naltrexone and Oxandrolone Interaction: Avoid | Peptide Database

Join others researching Raloxifene — share findings, ask questions, and learn from real experiences Raloxifene is a second-generation selective estrogen receptor modulator (SERM) FDA-approved for the prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction. Unlike tamoxifen, raloxifene has a benzothiophene core rather than a triphenylethylene backbone, giving it a distinct tissue-selectivity profile. In performance enhancement contexts, raloxifene is widely regarded as the preferred SERM for gynecomastia reversal because of its stronger antagonist activity at breast tissue estrogen receptors with fewer off-target effects. However, raloxifene is not an effective standalone post-cycle therapy drug because it does not stimulate the hypothalamic-pituitary-testicular axis as robustly as tamoxifen or enclomiphene. Its weaker antagonism at hypothalamic estrogen receptors means it produces comparatively modest elevations in LH and FSH, making it poorly suited for driving testosterone recovery after anabolic steroid cycles. Raloxifene carries a lower risk of endometrial stimulation than tamoxifen, as it acts as an estrogen antagonist rather than a partial agonist in uterine tissue. Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity. This strong breast-tissue antagonism underlies its effectiveness for gynecomastia treatment and breast cancer risk reduction. In bone, raloxifene acts as an estrogen agonist, maintaining bone mineral density by inhibiting osteoclast-mediated resorption. Critically, raloxifene is a weaker antagonist at hypothalamic estrogen receptors compared to tamoxifen, which means it produces less disruption of estrogen-driven negative feedback on GnRH secretion. The result is a more modest increase in LH and FSH compared to tamoxifen, limiting its utility as a standalone PCT agent. In the uterus, raloxifene does not exhibit the partial agonist activity seen with tamoxifen, which translates to a substantially lower risk of endometrial hyperplasia and endometrial cancer with long-term use. Raloxifene is metabolized primarily through glucuronidation rather than CYP450-dependent oxidation, which reduces the potential for drug-drug interactions compared to tamoxifen.

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.